Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEPITEM
- Development stage
- Preclinical
- Lead developer
- University of Birmingham
- Modality
- Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a naturally occurring 14-amino acid peptide derived from the 14-3-3 zeta protein. Discovered by researchers at the University of Birmingham, it acts as a key regulator of the PEPITEM-adiponectin pathway, which maintains immune homeostasis by controlling leukocyte trafficking. PEPITEM is produced by B-cells in response to adiponectin stimulation and binds to Cadherin-15 (CDH15) on endothelial cells. This binding triggers the synthesis and release of sphingosine-1-phosphate (S1P), which subsequently acts on S1P receptors on T-cells to inhibit their trans-endothelial migration. By preventing excessive leukocyte infiltration into tissues, PEPITEM shows therapeutic potential for chronic inflammatory and autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.
- Other names
- Peptide Inhibitor of Trans-Endothelial Migration
02
Targets
EDG1 (Sphingosine-1-phosphate receptors)CDH15 (Cadherin-15)
Beyond the preview
Go deeper on PEPITEM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEPITEM.